Andrew Astor - Nephros CFO

NEPH
 Stock
  

USD 1.47  0.03  2.00%   

  CFO
Mr. Andrew Astor serves as Chief Financial Officer, Chief Operating Officer of the Company. Mr. Astor has served as the Companys Chief Financial Officer since February 2017. Prior to joining the Company, Mr. Astor was most recently President and Chief Financial Officer at Open Source Consulting Group, a growth stage services firm. Previously, he was a Managing Director at Synechron, a global consulting organization, from 2013 to 2015. From 2009 to 2013, he served as Vice President at Asurion, a large, privatelyheld insurance company. Mr. Astor was cofounder of the software company EnterpriseDB, and served as its CEO from 2004 to 2008. Mr. Astor was Vice President, Strategic Solutions at webMethods, a software firm, from 2002 to 2004 and Vice President of Transactional Products at Dun Bradstreet from 1998 to 2001. Prior to 1998, Mr. Astor held various roles at American Management Systems, SHLMCI Systemhouse, and Ernst Young
Age: 61  CFO Since 2018  MBA    
201 343 5202  https://www.nephros.com
Astor received his Bachelor of Arts in Mathematics from Clark University, and his MBA from The Wharton School at the University of Pennsylvania.

Andrew Astor Latest Insider Activity

Tracking and analyzing the buying and selling activities of Andrew Astor against Nephros stock is an integral part of due diligence when investing in Nephros. Andrew Astor insider activity provides valuable insight into whether Nephros is net buyers or sellers over its current business cycle. Note, Nephros insiders must abide by specific rules, including filing SEC forms every time they buy or sell Nephros'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Andrew Astor over three months ago via Macroaxis 
Nephros exotic insider transaction detected
Andrew Astor over six months ago via Macroaxis 
Nephros exotic insider transaction detected

Nephros Management Efficiency

Nephros has return on total asset (ROA) of (14.98) % which means that it has lost $14.98 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (25.51) %, meaning that it created substantial loss on money invested by shareholders. Nephros management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 1.12 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Nephros has a current ratio of 5.59, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Nephros until it has trouble settling it off, either with new capital or with free cash flow. So, Nephros' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nephros sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nephros to invest in growth at high rates of return. When we think about Nephros' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 1 records

CFO Since

Patricia YarringtonChevron Corp
2009
Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey. Nephros operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 34 people. Nephros (NEPH) is traded on NASDAQ Exchange in USA and employs 34 people.

Nephros Leadership Team

Elected by the shareholders, the Nephros' board of directors comprises two types of representatives: Nephros inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nephros. The board's role is to monitor Nephros' management team and ensure that shareholders' interests are well served. Nephros' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nephros' outside directors are responsible for providing unbiased perspectives on the board's policies.
Malcom Persen, Director
Daron Evans, CEO and President Acting CFO, Director and Member of Audit Committee
Thomas Gwydir, Director
Paul Mieyal, Director
Andrew Astor, CFO
Alisa Lask, Director
Matthew Rosenberg, Director
Moshe Pinto, Director
Arthur Amron, Independent Director
Oliver Spandow, Director

Nephros Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nephros a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Nephros Investors Sentiment

The influence of Nephros' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Nephros. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Nephros in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Nephros' short interest history, or implied volatility extrapolated from Nephros options trading.

Current Sentiment - NEPH

Nephros Investor Sentiment

Macroaxis portfolio users are evenly split in their trading attitude regarding investing in Nephros. What is your trading attitude regarding investing in Nephros? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Nephros using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Note that the Nephros information on this page should be used as a complementary analysis to other Nephros' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for Nephros Stock analysis

When running Nephros price analysis, check to measure Nephros' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nephros is operating at the current time. Most of Nephros' value examination focuses on studying past and present price action to predict the probability of Nephros' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Nephros' price. Additionally, you may evaluate how the addition of Nephros to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Is Nephros' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nephros. If investors know Nephros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nephros listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
15.8 M
Quarterly Revenue Growth YOY
-0.2
Return On Assets
-0.2
Return On Equity
-0.37
The market value of Nephros is measured differently than its book value, which is the value of Nephros that is recorded on the company's balance sheet. Investors also form their own opinion of Nephros' value that differs from its market value or its book value, called intrinsic value, which is Nephros' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nephros' market value can be influenced by many factors that don't directly affect Nephros' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nephros' value and its price as these two are different measures arrived at by different means. Investors typically determine Nephros value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nephros' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.